Skip to main content
. 2024 Mar 26;27(5):231. doi: 10.3892/etm.2024.12520

Figure 3.

Figure 3

SFRP4 was used to treat uterine leiomyosarcoma SKN cells at concentrations of 1.25 and 2.5 µg/ml, and the absorbance was measured. Cell viability was significantly suppressed in response to SFRP4 at a concentration of 2.5 µg/ml (n=8). *P=0.001 vs. the control. SFRP, secreted frizzled-related protein.